Phase
Condition
N/ATreatment
Riociguat
Macitentan Tablets
balloon pulmonary angioplasty
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the trial:
Age ≥ 18 years' old
Diagnosis of CTEPH
Not a candidate for PTE
Candidate for BPA based on suitable anatomy and disease burden
Treatment-naïve (no CTEPH or pulmonary arterial hypertension (PAH)-specific medicaltherapies) with plans for initiation of CTEPH/PAH-specific medical therapy andtreatment with BPA.
Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed).
Exclusion
Exclusion Criteria:
- Subjects presenting with any of the following will not be included in the trials:
Moderate to severe heart disease (LVEF < 45% or severe LV Hypertrophy)
Sarcoidosis
Active cancer
Sickle cell anemia
Liver disease (Childs-Pugh class C)
Prisoners
Pregnant, planning pregnancy or lactating
Conditions that will prohibit MRI scanning (metal in eye, claustrophobia,inability to lie supine)
Contraindication to riociguat or macitentan
Medical or psychological conditions which, in the opinion of the investigator,might create undue risk to the subject or interfere with the subject's abilityto comply with the protocol requirements
Study Design
Study Description
Connect with a study center
Duke University Medical Center
Durham, North Carolina 27710
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.